Synthetic versus autologous reconstruction of the medial patellofemoral ligament
| ISRCTN | ISRCTN16657952 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN16657952 |
| IRAS number | 211907 |
| Secondary identifying numbers | IRAS Project ID 211907 |
- Submission date
- 20/10/2016
- Registration date
- 03/03/2017
- Last edited
- 14/03/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
The medial patellofemoral ligament (MPFL) helps to keep the kneecap in the right position. If the MPFL is torn (ruptured), the knee cap is displaced from its normal position. There are many ways to address the unstable knee cap. One such way is to operate, and there are different procedures that can be performed. One method is to use the patient’s own hamstring tendons to restore the knee cap (autologous hamstring graft). An alternative is to use a synthetic mesh to restore stability. Both methods have been successfully used, with good results. However, no study has been done to determine if one method is better than the other. The aim of this study is to address this issue, and compare the short-term results using both of these methods.
Who can participate?
Patients aged 14-25 with MPFL rupture. Only patients with 2 or more dislocations are considered for inclusion.
What is involved from you as a participant?
Participants are randomly allocated to one of two groups. One group undergoes MPFL reconstruction surgery with an autologous hamstring graft. The other group undergoes the same surgery but with a synthetic ligament instead. Participants attend outpatient appointments to track their recovery. Initial follow up is performed at 6 weeks after the operation as per routine follow up. Participants’ knees are assessed at 3, 6, 12, 18 and 24 months after the operation by a physiotherapist.
What are the benefits and risks of participating?
The information gathered may help assist and guide what surgical method we use and how we subsequently treat patients. The risks of surgery are no different between the groups, as the surgery is almost identical. Using the patient’s own hamstring tendons may slightly increase the duration of the surgery and may result in some additional bruising.
Where is the study run from?
Altnagelvin Area Hospital (UK)
When is the study starting and how long is it expected to run for?
September 2016 to January 2022 (updated 11/08/2020, previously: July 2022)
Who is funding the study?
Western Health and Social Care Trust (UK)
Who is the main contact?
Mr Danny Acton
Contact information
Scientific
c/o Miss Ellen Kelly
Altnagelvin Area Hospital
Glenshane Road
Londonderry
BT47 6SB
United Kingdom
| Phone | +44 (0)287 134 5171 |
|---|---|
| danny.acton@westerntrust.hscni.net |
Study information
| Study design | Randomised control prospective single-centre study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | ISRCTN16657952_PIS_14Nov16.docx |
| Scientific title | Synthetic versus autologous reconstruction (Syn-VAR) study for recurrent patellar instability: a prospective randomised pilot study |
| Study objectives | To compare autologous hamstring medial patellofemoral ligament (MPFL) reconstruction with vastus mediu obliquitus (VMO) advancement against synthetic graft MPFL reconstruction with VMO advancement. |
| Ethics approval(s) | Office for Research Ethics Committees of Northern Ireland, 21/08/2017, ref: ORECNI ID 17/NI/0129 |
| Health condition(s) or problem(s) studied | Recurrent patellar instability with MRI-proven MPFL injury |
| Intervention | Patients will be randomised to receive either: 1. MPFL reconstruction with autologous hamstring graft (h-MPFL) 2. Synthetic woven ligament (s-MPFL) Both are in combination with VMO advancement. Once randomised, the patients will have the procedure explained, and have the option to proceed, or opt out pre-operatively. The operating surgeon will not be blinded to the operative procedure. All operations will be performed by a single soft tissue knee specialist surgeon, using their default surgical technique. The only difference in surgical procedure will be the choice of graft used Pre-operative clinical assessment will be performed by a registrar or consultant. Pre-operative AP, lateral and skyline view radiographs will be reviewed. Measurements for patella alta will be performed (Insall-Salvati and Gaton-Deschamp indices) and congruence angles will be measured. Pre-operative MRI scans will also be reviewed and Tibial Tuberosity to Trochlear groove (TTTG) distances measured. Patients will be excluded if they require tibial tuberosity transfer or other osseus reconstructive procedures, or a lateral Z-lengthening procedure, as will the requirement for a multi-ligamentous knee reconstruction. This aims to keep the study population homogenous for the purposes of direct group comparison. Initial outpatient follow up will be performed at 6 weeks post-operatively as per routine follow up. Post-operative rehabilitation will be in accordance with departmentally agreed post-operative physiotherapy rehabilitation protocol. Functional score assessment will be performed at 3/6/12/18/24 months post-operatively by an outpatient physiotherapist associated with the study. Validated scoring questionnaires will be performed at each visit, to include Tegner-Lysholm activity scores, Kujala stability scores, and the Banff Patellar Instability Instrument (BPII). Primary end point will be two years, or MRI-confirmed re-rupture requiring revision surgery. Patients may opt out upon recruitment, or at any time throughout the study. Data collected at clinical review will be included up to the point of opt out for statistical analysis. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | Functional outcomes, measured using the Tegner activity scale, Lysholm Score and the Banff Patellar Instability Index Score, pre-operatively followed by post-operative checks at 6 weeks, and then again at 3/6/12/24 months post-operatively |
| Secondary outcome measures | 1. Revision surgery 2. Recurrent dislocation The timepoints for revision and recurrent dislocation are not specified, as these will be defined by these events occurring in the patient after surgery. |
| Overall study start date | 01/09/2016 |
| Completion date | 31/01/2022 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Sex | Both |
| Target number of participants | 15 in each arm (total 30) |
| Total final enrolment | 20 |
| Key inclusion criteria | Current inclusion criteria as of 29/01/2018: 1. Aged 14-25 years 2. Confirmed medial patellofemoral ligament rupture on MRI 3. Pre-operative AP, lateral and skyline radiographs 4. Unilateral or bilateral symptoms 5. Clinical signs of patellar instabiltity 6. Closed proximal tibial physes 7. Only patients with 2 or more dislocations will be considered for inclusion Previous inclusion criteria from 08/09/2017 to 29/01/2018: 1. Aged 14-25 years 2. Confirmed medial patellofemoral ligament rupture on MRI 3. Pre-operative AP, lateral and skyline radiographs 4. Unilateral or bilateral symptoms 5. Clinical signs of patellar instabiltity 6. Closed proximal tibial physes Original inclusion criteria: 1. Aged 14-25 years 2. Confirmed medial patellofemoral ligament rupture on MRI 3. Pre-operative AP, lateral and skyline radiographs 4. Unilateral or bilateral symptoms |
| Key exclusion criteria | Current exclusion criteria as of 14/02/2018: 1. Patients requiring bony transfer procedures (e.g., tibial tuberosity transfer) 2. Patients requiring a lateral release or Z-lengthening of the lateral structures 3. Patients with lateral compression signs on the skyline radiographs 4. Patients with confirmed multi-ligamentous knee injury 5. Patients with confirmed osteochondral lesions on MRI or plain radiograph pre-operatively 6. Patients who have previously underwent surgery 7. Abnormal hip or hindfoot pathology 8. Excessive femoral anteversion (>30 degrees) and/or excessive external tibial torsion (>40 degrees) 9. Excessive coronal plane deformity 10. Dejour grade C/D trochlear dysplasia 11. Excessive patellar tilt as measured by the Angle or Laurin and Fulkerson Angle methods. 12. Skeletally immature patients 13. Eastablish radiological changes of arthritis 14. Patients with confirmed hypersensitivity to synthetic graft material 15. A TT-TG distance >20mm on MRI/CT Previous exclusion criteria from 08/09/2017 to 14/02/2018: 1. Patients requiring bony transfer procedures (e.g., tibial tuberosity transfer) 2. Patients requiring a lateral release or Z-lengthening of the lateral structures 3. Patients with lateral compression signs on the skyline radiographs 4. Patients with confirmed multi-ligamentous knee injury 5. Patients with confirmed osteochondral lesions on MRI or plain radiograph pre-operatively 6. Patients who have previously underwent surgery 7. Abnormal hip or hindfoot pathology 8. Excessive femoral anteversion (>30 degrees) and/or excessive external tibial torsion (>40 degrees) 9. Excessive coronal plane deformity 10. Dejour grade D trochlear dysplasia 11. Excessive patellar tilt as measured by the Angle or Laurin and Fulkerson Angle methods. 12. Skeletally immature patients 13. Eastablish radiological changes of arthritis 14. Patients with confirmed hypersensitivity to synthetic graft material 15. Insall-Salvati >1.2, Gaton Dechamp <1.3 or TT-TG >20mm Original exclusion criteria: 1. Patients requring bony transfer procedures (e.g., tibial tuberosity transfer) 2. Patients requiring a lateral release or Z-lengthening of the lateral structures 3. Patients with lateral compression signs on the skyline radiographs 4. Patients with confirmed multi-ligamentous knee injury 5. Patients with confirmed osteochondral lesions on MRI or plain radiograph pre-operatively 6. Patients who have previously underwent surgery |
| Date of first enrolment | 01/10/2017 |
| Date of final enrolment | 31/07/2020 |
Locations
Countries of recruitment
- Northern Ireland
- United Kingdom
Study participating centre
Londonderry
BT47 6SB
United Kingdom
Sponsor information
Hospital/treatment centre
R&D Office CTRIC
Altnagelvin Area Hospital
Glenshane Road
Londonderry
BT47 6SB
Northern Ireland
United Kingdom
| Phone | +44 (0)287 161 1156 |
|---|---|
| sally.doherty@westerntrust.hscni.net | |
"ROR" |
https://ror.org/00sb42p15 |
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | 31/07/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | The results will be published in a medical peer-reviewed journal once the study has completed 2 years. As stated in the study protocol, the information will be kept for 5 years in total, so that patients may be recalled or surveyed at 5 years post-operatively to assess longer term function after both repair methods. |
| IPD sharing plan | Data will be kept on a secure computer account on the trust server, with password access only for the study investigators. This will be kept before being electronically destroyed after completion of the study, in line with local data protection policies. There are no plans to make this freely available in the interests of patient anonymity and confidentiality. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | 14/11/2016 | 03/03/2017 | No | Yes | |
| Protocol article | protocol | 03/05/2018 | Yes | No | |
| Poster results | 14/03/2023 | No | No | ||
| HRA research summary | 26/07/2023 | No | No |
Additional files
- ISRCTN16657952_PIS_14Nov16.docx
- Uploaded 03/03/2017
- ISRCTN16657952_POSTER.pptx
Editorial Notes
14/03/2023: Poster uploaded.
11/07/2022: The total final enrolment was added.
11/08/2020: The following changes were made to the trial record:
1. The overall end date was changed from 31/07/2022 to 31/01/2022.
2. The plain English summary was updated to reflect these changes.
12/06/2020: Contact details updated.
04/05/2020: Due to current public health guidance, recruitment for this study has been paused.
13/03/2020: The following changes have been made:
1. The recruitment end date has been changed from 31/12/2018 to 31/07/2020.
2. The intention to publish date has been changed from 01/09/2019 to 31/07/2022.
3. The overall trial end date has been changed from 01/09/2018 to 31/07/2022.
4. The plain English summary has been updated to reflect the changes above.
06/09/2019: Internal review.
08/05/2018: Publication reference added.
14/02/2018: Exclusion criteria updated.
29/01/2018: Inclusion criteria updated.
23/01/2018: The target number of participants was changed from 10 in each arm (total 20) to 15 in each arm (total 30).
08/09/2017: Ethics approval information has been added. Inclusion and exclusion criteria has been updated. The recruitment dates have been updated from 01/12/2016-30/11/2017 to 01/10/2017-31/12/2018.
